中国将CARSgen的CAR-T治疗添加到保险目录中, 增加多位骨髓瘤患者获得治疗的机会。 China adds CARsgen’s zevor-cel CAR-T therapy to its insurance catalog, boosting access for multiple myeloma patients.

卡斯根治疗公司的Zevor-cel,一种针对复发性或耐火性多发性骨髓瘤的BCMA向性CAR-T疗法,已被添加到中国2025年商业健康保险创新药物目录中. CARsgen Therapeutics' zevor-cel, a BCMA-targeted CAR-T therapy for relapsed or refractory multiple myeloma, has been added to China’s 2025 Commercial Health Insurance Innovative Drug Catalogue. 中国的NMPA于2024年2月得到中国的NMPA批准,并由CARSgen通过华东医药的商业化开发,该疗法在第一阶段试验中表现出100%的响应率和78.6%的完整或严格的完整响应率,中位无进展存活时间为44.1个月,没有严重的副作用。 Approved by China’s NMPA in February 2024 and developed by CARsgen with commercialization by Huadong Medicine, the therapy showed a 100% response rate and 78.6% complete or stringent complete responses in a Phase I trial, with a median progression-free survival of 44.1 months and no severe side effects. 在2025年头9个月以170份确认的订单大力及早通过中国的多层次保险制度,扩大患者获得服务的机会。 The inclusion aims to expand patient access through China’s multi-layered insurance system, following strong early adoption with 170 confirmed orders in the first nine months of 2025.